期刊
DRUG DISCOVERY TODAY
卷 15, 期 9-10, 页码 354-364出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.03.009
关键词
-
资金
- National Institutes of Health [CA78590, CA111294, CA133774, CA131944]
- NATIONAL CANCER INSTITUTE [U01CA111294, R01CA133774, R01CA131944, R01CA078590] Funding Source: NIH RePORTER
The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutic treatments against highly aggressive, metastatic, recurrent, and lethal cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据